<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Histologic transformation of follicular lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Histologic transformation of follicular lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Histologic transformation of follicular lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the clinically indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. Histologic transformation (HT) refers to the evolution of a clinically indolent NHL (eg, FL) to a clinically aggressive lymphoma (eg, diffuse large B cell lymphoma) defined as those lymphomas in which survival of the untreated patient is measured in months.</p><p>HT of FL occurs at a rate of approximately 1 to 2 percent per year and is associated with rapid progression of lymphadenopathy, infiltration of extranodal sites, development of systemic symptoms, elevated serum lactate dehydrogenase, hypercalcemia, and often a poor prognosis.</p><p>The largest body of information dealing with HT is related to its occurrence in FL, which will be the focus of this review. HT has also been observed in other clinically indolent B cell lymphoproliferative disorders, including marginal zone lymphoma, lymphoplasmacytic lymphoma, and small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). HT that occurs in patients with SLL/CLL has been termed Richter transformation. (See  <a class="medical medical_review" href="/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>The epidemiology, diagnosis, and treatment of HT in patients with FL will be discussed here. Richter transformation is discussed separately, as is the diagnosis and management of FL that has not undergone HT.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H21731960"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H6"><span class="h2">Frequency of transformation</span><span class="headingEndMark"> — </span>Approximately 15 percent of patients with FL will undergo HT during their disease course at an estimated annual rate of 1 to 2 percent [<a href="#rid1">1-6</a>].</p><p>Since not all patients undergo biopsy at the time of progression, studies have tried to estimate rates of HT using both biopsy-proven cases and clinical HT. Clinical HT includes patients with a sudden rise in lactate dehydrogenase (LDH) to twice the upper limit of normal, rapid discordant localized nodal growth, new involvement of unusual extranodal sites, new unexplained systemic B symptoms (fever, weight loss, night sweats), and/or the development of hypercalcemia.</p><p>In a prospective observational series of over 600 patients with newly diagnosed FL followed for a median of five years, 60 patients (11 percent) developed clinical or biopsy-proven HT at an estimated rate of 2 percent per year [<a href="#rid3">3</a>]. In this study, 85 percent of HT was biopsy proven.</p><p>The frequency of HT was also analyzed in the Primary <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> and Maintenance (PRIMA) study, which included over 1000 patients with previously untreated FL who had demonstrated an initial response to chemoimmunotherapy with R-CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus rituximab; 75 percent), R-CVP (cyclophosphamide, vincristine, and prednisone plus rituximab; 22 percent), or R-FCM (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, cyclophosphamide, and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> plus rituximab; 3 percent) [<a href="#rid4">4</a>]. After a median follow-up of six years, 463 patients had progressive disease. Among the 194 patients who had histologic confirmation of relapse, 40 patients (21 percent) demonstrated HT and 154 patients (79 percent) had untransformed FL. Median time to recurrence was shorter in those with transformed FL (9.6 versus 22.8 months).</p><p class="headingAnchor" id="H7"><span class="h2">Risk factors for transformation</span><span class="headingEndMark"> — </span>Risk factors for the ultimate development of HT at the time of initial presentation of FL were evaluated among over 2600 patients prospectively enrolled in the National LymphoCare Study [<a href="#rid5">5</a>]. After a median follow-up of 6.8 years, HT was identified clinically or pathologically in 14 percent. The following factors were associated with an increased risk of confirmed or suspected HT:</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;1 extranodal site – hazard ratio (HR) 1.39</p><p class="bulletIndent1"><span class="glyph">●</span>Eastern Cooperative Oncology Group (ECOG) performance status &gt;1 – HR 2.12</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum level of LDH – HR 1.57</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic B symptoms (fevers, night sweats, weight loss) – HR 1.35</p><p></p><p>Risk factors reported in other studies have included:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III or IV disease [<a href="#rid7">7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum level of LDH [<a href="#rid4">4,5,7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-2 microglobulin level &gt;3 mg/L [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin &lt;3.5 g/dL [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Grade III histology [<a href="#rid4">4,9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>High Follicular Lymphoma International Prognostic Index (FLIPI)  (<a class="graphic graphic_table graphicRef55987" href="/d/graphic/55987.html" rel="external">table 1</a>) [<a href="#rid4">4,9</a>] or International Prognostic Index (IPI)  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 2</a>) [<a href="#rid4">4,7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of complete remission following initial treatment [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Early treatment failure (eg, progression within 24 months of chemoimmunotherapy) [<a href="#rid4">4,10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>"Diffuse large B-cell lymphoma-like" pattern on genome sequencing [<a href="#rid11">11</a>]</p><p></p><p>In three studies, whether the patient received immediate or delayed treatment did not affect the risk of development of HT [<a href="#rid4">4,12,13</a>], while in a fourth study those who received delayed treatment had a higher risk of HT (HR 1.9; 95% CI 1.2-2.9) [<a href="#rid7">7</a>].</p><p>While positron emission tomography (PET) imaging can guide the selection of an appropriate biopsy site in suspected HT, increased uptake on pretreatment PET imaging does not appear to predict future HT. A retrospective analysis of patients with previously untreated advanced-stage FL enrolled on the prospective GALLIUM study did not detect higher rates of HT in patients with baseline maximum standardized uptake value (SUV) &gt;10 or &gt;20 [<a href="#rid14">14</a>]. Similarly, the range of SUVs at baseline was not predictive of future HT. Importantly, patients with biopsy-proven HT at the time of FL diagnosis were excluded from this study. As such, these results do not address the role of PET in assessing suspected HT at the time of diagnosis or beyond.</p><p class="headingAnchor" id="H21731981"><span class="h1">PATHOBIOLOGY</span><span class="headingEndMark"> — </span>HT is a nonlinear evolution of the FL tumor population. At the time of diagnosis, most cases of FL are comprised of multiple clones [<a href="#rid15">15</a>]. HT is thought to develop through expansion of an aggressive clone that may have been very small at the time of presentation [<a href="#rid15">15,16</a>]. The following sections describe the pathobiology of HT. The pathobiology of FL and diffuse large B cell lymphoma (DLBCL) are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/16646.html" rel="external">"Pathobiology of follicular lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Cytogenetics</span><span class="headingEndMark"> — </span>While the acquisition and accumulation of additional genetic abnormalities are commonly seen in HT, no single cytogenetic abnormality appears to be solely responsible for this transformation. The overwhelming majority of cases of DLBCL evolving from FL are clonally related [<a href="#rid17">17</a>]. In contrast, in histologic (Richter) transformation of chronic lymphocytic leukemia (CLL), the CLL clone and the transformed clone are related in only 60 percent of cases [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>A large number of other nonrandom secondary cytogenetic abnormalities have been described in FL [<a href="#rid19">19,20</a>]. Although many of these accompany disease progression in which follicular architecture is retained, as well as following HT, detailed analysis has demonstrated widespread secondary chromosomal abnormalities at initial diagnosis and during the course of FL [<a href="#rid21">21</a>]. </p><p>The most common translocation in FL is t(14;18) (BCL-2::IgH), being present in 85 percent of patients. Following HT, the BCL-2::IgH rearrangement persists in virtually all cases, with identical nucleotide sequences in the original FL and the DLBCL samples [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Cytogenetics'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Gene alterations</span><span class="headingEndMark"> — </span>Specific genetic lesions have been identified in HT and provide insight into its pathogenesis [<a href="#rid23">23-25</a>]. These include alterations in genes regulating proliferation, control of the cell cycle, deoxyribonucleic acid (DNA) damage response, and programmed cell death.</p><p>Mutations of the <em>TP53</em> gene have been reported in approximately 25 to 80 percent of cases of transformed FL [<a href="#rid26">26,27</a>]. <em>TP53</em> is similarly inactivated in approximately 20 percent of transformed mucosa-associated lymphoid tissue (MALT) lymphomas by deletion or mutation [<a href="#rid28">28</a>]. In a report of serial biopsies from patients with FL, <em>TP53</em> mutations were observed in 28 percent of cases [<a href="#rid29">29</a>]. Although <em>TP53</em> mutations were not present at diagnosis, in subsequent biopsies where the histology remained FL, 14 percent of cases had mutations, providing evidence that <em>TP53</em> mutations can precede HT, occurring from six months to four years prior to transformation.</p><p>Given the central role of the B cell lymphoma 6 (<em>BCL-6</em>) gene in DLBCL, investigators have examined <em>BCL-6</em> alterations in HT [<a href="#rid30">30,31</a>]. In one study, <em>BCL-6</em> translocations or deletions were reported in 39 percent of patients with FL who went on to develop HT versus 14 percent in those that did not transform [<a href="#rid32">32</a>]. However, both loss and gain of <em>BCL-6</em> translocations were observed, suggesting that <em>BCL-6</em> translocation is not required for HT. (See  <a class="medical medical_review" href="/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Aberrant BCL6 expression'</a> and  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Alterations in BCL6'</a>.)</p><p>FL is associated with the overexpression of the oncogene B cell leukemia/lymphoma 2 (<em>BCL-2</em>), located on chromosome band 18q21. Overexpression is typically due to a translocation between the long arm of chromosome 18 and one of the three immunoglobulin genes. In one study, mutations in the <em>BCL-2</em> coding sequence were found in 12 percent of cases at diagnosis and 53 percent at HT [<a href="#rid33">33</a>]. <em>BCL-2</em> mutations at diagnosis were associated with an increased risk of transformation (hazard ratio 3.6) and a shorter median survival (9 versus 20 years). </p><p>At the time of transformation, approximately one-quarter of cases meet criteria for high-grade B cell lymphoma with <em>MYC</em> and <em>BCL-2</em> rearrangements ("double-hit" lymphoma) [<a href="#rid34">34</a>]. While "double-hit" lymphoma is associated with a worse prognosis than newly diagnosed DLBCL, the prognostic impact of these mutations on HT is not well established. (See  <a class="medical medical_review" href="/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Double hit lymphoma'</a> and  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'High-grade lymphoma with rearrangements of MYC plus BCL2 and/or BCL6 ("double-hit")'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Cell of origin</span><span class="headingEndMark"> — </span>Cell of origin can be assessed using gene expression profiling (GEP), immunohistochemistry algorithms (eg, Tally and Hans), and the Lymph2Cx platform. When assessed at the time of transformation, the most cases (approximately 80 percent) will have a pattern consistent with a germinal center B (GCB) cell of origin, the prognostic impact of which has not been clearly established [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Cell of origin studies'</a>.)</p><p class="headingAnchor" id="H21731973"><span class="h1">CLINICAL PRESENTATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H21731562"><span class="h2">When to suspect HT</span><span class="headingEndMark"> — </span>For patients with FL, we have a low threshold to biopsy at the time of progression prior to retreatment to confirm relapse and evaluate for HT. Imaging with a combined positron emission tomography/computed tomography (PET/CT) scan provides information about the anatomic areas of involvement and their metabolic activity. Biopsy should aim to sample a lymph node with the highest activity on PET. (See <a class="local">'Evaluation'</a> below.)</p><p>HT is clinically aggressive, and patients frequently display features commonly seen in patients initially presenting with a diagnosis of clinically aggressive non-Hodgkin lymphoma (NHL), such as diffuse large B cell lymphoma (DLBCL). These are described in more detail separately. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Clinical presentation'</a>.)</p><p>The following findings raise the clinical suspicion for HT: </p><p class="bulletIndent1"><span class="glyph">●</span>Early treatment failure (eg, progression within 24 months of initial chemoimmunotherapy)</p><p class="bulletIndent1"><span class="glyph">●</span>Focal intense uptake on imaging with PET (eg, standardized uptake value [SUV] &gt;10)  </p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of lymphadenopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Infiltration of uncommon extranodal sites (excluding the bone marrow)</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms (eg, fever, weight loss, night sweats)</p><p class="bulletIndent1"><span class="glyph">●</span>Sudden decline in performance status</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase (LDH)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia</p><p></p><p>A retrospective single-center analysis of 325 patients with newly diagnosed FL, followed for a median of 15 years, had a cumulative incidence of HT by 10 years of 28 percent [<a href="#rid7">7</a>]. Of the 111 patients who underwent biopsy at first recurrence, 22 had HT. When compared with patients whose repeat biopsy showed FL without HT, patients with biopsy-proven HT were more likely to have the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated LDH (79 versus 17 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin &lt;12 g/L (53 versus 23 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years (68 versus 35 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>High International Prognostic Index (IPI) score (<a class="calc calc_professional" href="/d/html/87307.html" rel="external">calculator 1</a>) (50 versus 20 percent)</p><p></p><p>In another study of 60 patients found to have HT at the time of diagnosis, the following adverse clinical characteristics were found at the time of presentation [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated disease – 97 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum LDH levels – 55 percent</p><p class="bulletIndent1"><span class="glyph">●</span>More than one extranodal site involved – 50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Poor performance status – 33 percent</p><p></p><p>HT has been reported at high rates among patients with early treatment failure. As an example, in a retrospective study of approximately 300 patients with FL, clinical or biopsy-proven HT was reported in 76 percent of patients progressing within 24 months of initial treatment with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid10">10</a>]. In another analysis of 194 patients with biopsy confirmation of progressive disease after chemoimmunotherapy in the Primary Rituximab and Maintenance (PRIMA) study, 79 percent had untransformed FL, and 21 percent had HT [<a href="#rid4">4</a>]. Median time to progression was shorter in those with transformed FL (9.6 versus 22.8 months).</p><p class="headingAnchor" id="H1427073885"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of a patient with suspected HT aims to identify the best lymph node for biopsy. Imaging with a combined 18F-fluorodeoxyglucose (FDG) PET/CT scan provides information about the anatomic areas of involvement and their metabolic activity. Biopsy should aim to sample a lymph node with the highest activity on PET; lesions with an SUV &gt;10 have a higher likelihood of transformation [<a href="#rid36">36,37</a>].</p><p>Only an excisional biopsy of an intact node consistently allows sufficient tissue for histologic, immunologic, and molecular biologic assessment, and classification by experienced hematopathologists. In general, lymph nodes larger than 2.25 cm<sup>2</sup> (ie, a node with biperpendicular diameters of 1.5 x 1.5 cm) or 2 cm in a single diameter have the best diagnostic yields. Peripheral lymph nodes are generally preferred to other lymph nodes for diagnostic biopsy because they are easily accessed and have a relatively high diagnostic yield. (See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Lymph node selection'</a>.)</p><p class="headingAnchor" id="H2702035689"><span class="h2">Pathologic features</span><span class="headingEndMark"> — </span>The diagnosis of HT requires a biopsy of involved tissue (usually a lymph node) that demonstrates loss of the follicular architecture and the accumulation of large tumor cells that resemble those of a clinically aggressive or highly aggressive NHL subtype. </p><p>In most cases, the pathology is consistent with DLBCL. Less commonly, FL evolves into Burkitt lymphoma, high-grade B cell lymphoma with <em>MYC</em> and <em>BCL-2</em> ("double-hit" lymphoma), or precursor lymphoid neoplasms (blastic/blastoid transformation) [<a href="#rid38">38,39</a>]. HT includes FL that evolves to grade 3b FL (sometimes called follicular large cell lymphoma). In contrast, tumors that evolve from a grade 1 to grade 2 or 3a are <strong>not</strong> considered HT. (See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Grade'</a>.)</p><p>On histology, the tumor demonstrates loss of the follicular architecture as well as an accumulation of large cells  (<a class="graphic graphic_picture graphicRef79473" href="/d/graphic/79473.html" rel="external">picture 1</a>). These tumors resemble de novo DLBCL or other aggressive or highly aggressive histologies, and have high Ki-67 staining  (<a class="graphic graphic_picture graphicRef77463" href="/d/graphic/77463.html" rel="external">picture 2</a>) and transferrin receptor-related protein, which are indicators of a high proliferative index [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Immunophenotype'</a>.)</p><p>Histology can vary greatly in different sections of the same lymph node. As such, careful examination of the sampled lymph node is key to determining whether a component of higher-grade lymphoma is present. Discordant histologic features suggest HT of a previously undiagnosed FL [<a href="#rid35">35,41-44</a>]. As an example, FL may be identified in the bone marrow in a patient with DLBCL in a lymph node. The detection of areas of DLBCL within the lymph node denotes HT. </p><p class="headingAnchor" id="H7778996"><span class="h1">PRETREATMENT EVALUATION AND STAGING</span><span class="headingEndMark"> — </span>Prior to initiating therapy, a pretreatment evaluation must establish the extent and sites of disease and the performance status of the patient. The pretreatment evaluation for patients with HT is the same as that of patients with de novo diffuse large B cell lymphoma. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Pretreatment evaluation'</a>.)</p><p>Most patients with HT will have advanced-stage disease (usually stage III or IV  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 3</a>)). While HT may occur at a single site, it is difficult to prove that other sites of FL have not transformed. As such, most patients with HT are treated as if they have advanced-stage aggressive lymphoma. Rare cases of localized HT may be managed as limited-stage aggressive lymphoma.</p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H4027421749"><span class="h2">Choosing a management approach</span><span class="headingEndMark"> — </span>The goal of therapy for most patients is to eliminate the aggressive component of disease (ie, the histologically transformed cells) while minimizing toxicity. While patients may be cured of the aggressive component, they are usually not cured of the indolent component (ie, FL). Therapy directed at the palliation of symptoms alone may be appropriate for patients unlikely to tolerate the toxicity of more aggressive treatment regimens.</p><p>Management incorporates one or more of the following  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional chemoimmunotherapy (eg, R-CHOP [<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>], R-pola-CHP [rituximab, <a class="drug drug_general" data-topicid="121575" href="/d/drug information/121575.html" rel="external">polatuzumab vedotin</a>, cyclophosphamide, doxorubicin, prednisone], EPOCH-R [<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, doxorubicin, vincristine, cyclophosphamide, and prednisone plus rituximab], R-ICE [rituximab, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and etoposide])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="121575" href="/d/drug information/121575.html" rel="external">Polatuzumab vedotin</a> (anti-CD79b antibody-drug conjugate) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-CD20 antibodies, including CD20 x CD3 bispecific monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="141793" href="/d/drug information/141793.html" rel="external">glofitamab</a>, <a class="drug drug_general" data-topicid="141559" href="/d/drug information/141559.html" rel="external">epcoritamab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-CD19 antibodies (eg, <a class="drug drug_general" data-topicid="129156" href="/d/drug information/129156.html" rel="external">tafasitamab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="131455" href="/d/drug information/131455.html" rel="external">Loncastuximab tesirine</a> (an anti-CD19 antibody-drug conjugate)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD19-directed chimeric antigen receptor (CAR)-T cell therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose therapy followed by autologous hematopoietic cell transplantation (HCT)</p><p></p><p>There is no agreed-upon standard treatment for HT. Management is largely guided by data from observational studies and retrospective analyses and by extrapolation of data on the treatment of de novo aggressive histologies. Whenever possible, patients should be encouraged to enroll on clinical trials. </p><p>Outside of a clinical trial, our preferred therapy depends upon: </p><p class="bulletIndent1"><span class="glyph">●</span>Prior treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor aggressiveness (eg, histology and molecular markers)</p><p class="bulletIndent1"><span class="glyph">●</span>International Prognostic Index (IPI) (<a class="calc calc_professional" href="/d/html/87307.html" rel="external">calculator 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Response to chemoimmunotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Patient fitness and comorbidities</p><p class="bulletIndent1"><span class="glyph">●</span>Patient values and preferences </p><p></p><p>This approach is generally consistent with that of major guidelines, including those from the National Comprehensive Cancer Network and the British Society for Haematology [<a href="#rid45">45,46</a>]. </p><p>A discussion about values and preferences can help to guide therapy. Palliative care alone may be in the patient's best interest, especially in the setting of multiply relapsed disease for which both the indolent and aggressive components may be particularly difficult to control. Since FL frequently presents in older adults, many patients will not be able to tolerate some of the more aggressive treatment options. </p><p>Individuals differ in the value they place on the avoidance of toxicity and the delay of further anti-lymphoma treatment. Different patients who are equally informed of these risks and benefits are likely to make different treatment decisions.</p><p>Patients with HT have a risk of central nervous system (CNS) recurrence of approximately 2 to 5 percent and usually do not warrant CNS prophylaxis. The decision to administer CNS prophylaxis should be decided on a case-by-case basis. The decision to administer CNS prophylaxis and the choice of regimen is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma", section on 'CNS prophylaxis'</a>.)</p><p class="headingAnchor" id="H2517485640"><span class="h3">Prior chemoimmunotherapy</span></p><p class="headingAnchor" id="H705842462"><span class="h4">Induction chemoimmunotherapy</span><span class="headingEndMark"> — </span>Approximately one-half of patients will have received prior chemoimmunotherapy for FL (eg, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, R-CHOP) [<a href="#rid47">47</a>]. For such patients, a different chemotherapy regimen is given to control the aggressive component prior to consolidation with either CD-19-directed CAR-T cell therapy or autologous HCT.</p><p>The preferred chemoimmunotherapy regimen depends on what regimens the patient has been exposed to and the type of HT  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). Either rituximab-based or obinutuzumab-based combination regimens may be used. Based on extrapolation of data from studies in follicular lymphoma, obinutuzumab-based combinations (eg, O-CHOP [<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>]) may provide greater disease control for the indolent component. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Obinutuzumab-based regimens'</a>.) </p><p>Data supporting this choice are largely extrapolated from studies of those with de novo aggressive lymphoma, which are described separately. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse large B cell lymphoma-like HT without exposure to R-CHOP or O-CHOP</strong> – For most patients with HT resembling diffuse large B cell lymphoma (DLBCL) without prior exposure to R-CHOP or O-CHOP, we offer therapy akin to that used for previously untreated DLBCL. Typically, we offer six cycles of either: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>R-CHOP  (<a class="graphic graphic_table graphicRef63586" href="/d/graphic/63586.html" rel="external">table 4</a>), or</p><p class="bulletIndent2"><span class="glyph">•</span>R-pola-CHP </p><p></p><p class="bulletIndent1">R-pola-CHP may be preferred over R-CHOP for those with an IPI ≥2 based on the worse prognosis of such patients and initial results of a randomized trial (POLARIX) that suggested superior efficacy and similar toxicity with R-pola-CHP when compared versus R-CHOP for the initial treatment of de novo DLBCL (trial excluded patients with HT) [<a href="#rid48">48</a>]. However, R-CHOP remains a reasonable alternative, especially given that a high percentage of patients with IPI ≥2 may have a germinal center B cell-like subtype of DLBCL, a subgroup that did not demonstrate a clear benefit from R-pola-CHP on exploratory analysis of POLARIX. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Double-hit HT without exposure to R-CHOP or O-CHOP</strong> – For younger, fit patients with double-hit HT (those with both <em>MYC</em> and <em>BCL-2 </em>rearrangement), we suggest six cycles of dose-adjusted EPOCH-R  (<a class="graphic graphic_table graphicRef88411" href="/d/graphic/88411.html" rel="external">table 5</a>) rather than R-CHOP or R-pola-CHP. This preference is based on extrapolation of data from a meta-analysis of 11 studies of de novo double-hit HT that demonstrated improved progression-free survival (PFS) yet greater toxicity with EPOCH-R or CODOX-M with IVAC (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> alternating with <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>) when compared with R-CHOP [<a href="#rid49">49</a>]. R-CHOP, R-pola-CHP, or R-mini-CHOP (reduced dose of CHOP with conventional dose of rituximab) are acceptable alternatives for older or frail patients with double-hit HT. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'High-grade lymphoma with rearrangements of MYC plus BCL2 and/or BCL6 ("double-hit")'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse large B cell lymphoma-like or double-hit HT with prior exposure to R-CHOP or O-CHOP</strong> – For patients with HT resembling DLBCL or double-hit HT who have received prior R-CHOP or O-CHOP, we offer a regimen used for relapsed DLBCL (eg, R-ICE [<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>], R-DHAP [rituximab, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, high-dose <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>], R-ESHAP [rituximab, etoposide, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>, cytarabine, cisplatin]). We assess response after two or three cycles. (See  <a class="medical medical_review" href="/d/html/4708.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Selection of salvage chemotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-grade B-cell lymphoma, NOS </strong>– For those with HT resembling high-grade B-cell lymphoma, not otherwise specified (previously "Burkitt-like" lymphoma), we offer six cycles of dose-adjusted EPOCH-R. While CODOX-M with IVAC has demonstrated superior outcomes in young patients with de novo Burkitt lymphoma, patients with HT are older than those with de novo Burkitt lymphoma. Selected younger adults and/or those with CNS involvement may be candidates for the more aggressive CODOX-M with IVAC regimen. (See  <a class="medical medical_review" href="/d/html/4734.html" rel="external">"Treatment of Burkitt leukemia/lymphoma in adults"</a>.)</p><p></p><p class="headingAnchor" id="H657962653"><span class="h4">Consolidation with chimeric antigen receptor T or transplant</span><span class="headingEndMark"> — </span>Approximately one-half of patients will have received prior chemoimmunotherapy for FL (eg, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, R-CHOP, O-CHOP) [<a href="#rid47">47</a>]. For such patients, we suggest treatment with a different chemoimmunotherapy followed by consolidation with either CAR-T cell therapy or autologous HCT rather than chemoimmunotherapy alone  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). While many will achieve a complete response (CR) with chemoimmunotherapy, a high percentage will relapse in a short period if no further therapy is given. Consolidation attempts to postpone relapse and improve overall survival (OS). CAR-T cell therapy is preferred for those who do not achieve a CR. Either CAR-T cell therapy or autologous HCT is a reasonable option for patients achieving a CR. </p><p>Our preference to proceed with consolidation is based on retrospective studies and case series that have demonstrated inferior outcomes in patients with prior exposure to anthracyclines. In one report of 35 patients treated after HT with R-CHOP or a similar therapy, OS at five years was worse among those who had received R-CHOP before HT (21 versus 66 percent) [<a href="#rid3">3</a>]. Similar survival rates were noted in other studies of patients with HT after prior anthracycline-based therapy [<a href="#rid50">50,51</a>]. There is little information regarding the outcomes of patients with HT previously treated with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. While we proceed with consolidation in this population, other experts might reasonably suggest observation.</p><p>The use of CAR-T cell therapy and autologous HCT in HT is based on small studies of these modalities in patients with HT and extrapolation of larger studies of these modalities in relapsed aggressive lymphoma, many of which included a small population of patients with HT. </p><p>In those who achieve a CR with chemoimmunotherapy, either approach may be effective. Retrospective analyses have suggested that autologous HCT improves PFS and potentially OS in patients with chemotherapy-sensitive disease. Further details regarding efficacy and eligibility requirements for autologous HCT are presented separately. (See <a class="local">'Autologous transplant'</a> below and  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p>In those who do not achieve a CR with chemoimmunotherapy, we prefer CAR-T cell therapy based on extrapolation of data from randomized trials that have shown an OS advantage for CAR-T cell therapy over autologous HCT in patients with early first relapse (&lt;12 months) of DLBCL or primary refractory DLBCL [<a href="#rid52">52,53</a>]. Patients with FL with transformation to DLBCL were included in these trials, although they constituted a small percentage of patients enrolled. Further details regarding efficacy are presented separately. (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p>If CAR-T cell therapy is not available, patients with exposure to multiple lines of systemic therapy are also candidates for targeted therapies, including other antibody-based therapies. A choice among these is individualized. (See <a class="local">'Multiply relapsed or refractory disease'</a> below.)</p><p>Allogeneic HCT is only rarely used for HT because of substantial treatment-related mortality and toxicity. However, if CAR-T cell therapy and antibody-based treatments are not available or were previously administered, allogeneic HCT may be considered for select medically fit patients who achieve a CR or near-CR with salvage chemotherapy. It may also be an option for patients who are not felt to be candidates for autologous HCT due to poor stem cell reserve or quality. (See <a class="local">'Multiply relapsed or refractory disease'</a> below.)</p><p class="headingAnchor" id="H1130280686"><span class="h3">Little or no prior therapy</span><span class="headingEndMark"> — </span>Approximately one-half of patients will present with HT after having received little prior therapy (eg, single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or radiation therapy) or no prior therapy (eg, those presenting with transformation) [<a href="#rid47">47</a>]. For such patients, we suggest initial treatment with chemoimmunotherapy akin to that used for patients presenting with a de novo lymphoma of a similar histology  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). Data supporting this choice are largely extrapolated from studies of those with de novo lymphoma, which are described separately.</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with HT resembling DLBCL, we suggest a regimen used for the initial treatment of advanced-stage DLBCL. Typically, we offer six cycles of either R-CHOP  (<a class="graphic graphic_table graphicRef63586" href="/d/graphic/63586.html" rel="external">table 4</a>) or R-pola-CHP. R-pola-CHP is preferred for those with an IPI ≥2 based on extrapolation of data from patients with de novo DLBCL. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, patients with HT resembling DLBCL will have what appears to be localized transformation. While it is not possible to definitively rule out transformation at other sites, it is reasonable to offer such patients risk-adapted therapy akin to that used for limited-stage DLBCL. (See  <a class="medical medical_review" href="/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma", section on 'Initial treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with double-hit HT (those with both <em>MYC</em> and <em>BCL-</em>2 rearrangement or both), we offer regimens used for double-hit large cell lymphoma, typically six cycles of dose-adjusted EPOCH-R  (<a class="graphic graphic_table graphicRef88411" href="/d/graphic/88411.html" rel="external">table 5</a>) rather than R-CHOP or R-pola-CHP. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'High-grade lymphoma with rearrangements of MYC plus BCL2 and/or BCL6 ("double-hit")'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with high-grade B-cell lymphoma, not otherwise specified (previously "Burkitt-like" lymphoma), we suggest six cycles of dose-adjusted EPOCH-R rather than R-CHOP. While CODOX-M with IVAC has demonstrated superior outcomes in young patients with de novo Burkitt lymphoma, patients with HT are older than those with de novo Burkitt lymphoma. Selected younger adults and/or those with CNS involvement may be candidates for the more aggressive CODOX-M with IVAC regimen described separately. (See  <a class="medical medical_review" href="/d/html/4734.html" rel="external">"Treatment of Burkitt leukemia/lymphoma in adults"</a>.)</p><p></p><p>Further management depends on the response to chemoimmunotherapy  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Partial or no response – Those who have a partial response or no response are offered CAR-T cell therapy based on extrapolation of data from randomized trials that have shown an OS advantage for CAR-T cell therapy over autologous HCT in patients with early first relapse (&lt;12 months) of DLBCL or primary refractory DLBCL [<a href="#rid52">52,53</a>]. Patients with FL with transformation to DLBCL were included in these trials, although they constituted a small percentage of patients enrolled. (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete response – We do not routinely offer maintenance or consolidation to patients who achieve a CR. Patients with little or no therapy prior to HT have a better prognosis than those who have been treated with chemoimmunotherapy, and survival rates mirror those in the de novo DLBCL population [<a href="#rid5">5,47,50,51,54,55</a>]. Retrospective studies suggest that treatment of this group with chemoimmunotherapy alone results in CR rates over 80 percent and five-year survival rates of approximately 60 to 80 percent [<a href="#rid3">3,5,47,50,56</a>]. Unlike patients with de novo DLBCL, these patients are at risk for relapse of the indolent component, which was seen in 20 percent of patients in one study [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">There have been no prospective trials evaluating the use of maintenance therapy in patients with HT who attain a CR. In one multicenter retrospective analysis, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> maintenance improved PFS (94 versus 53 percent) but not OS in this population [<a href="#rid47">47</a>]. There was no demonstrated benefit from autologous HCT. In another retrospective analysis, rituximab maintenance did not have a significant impact on PFS or OS [<a href="#rid57">57</a>]. Maintenance rituximab is commonly employed after chemoimmunotherapy for newly diagnosed FL. In contrast, maintenance therapy does not appear to improve survival among patients who have completed initial chemoimmunotherapy for DLBCL. The use of maintenance rituximab in these two settings is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Use of maintenance'</a> and  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Incorporation of rituximab'</a>.)</p><p></p><p class="headingAnchor" id="H938259638"><span class="h3">Multiply relapsed or refractory disease</span><span class="headingEndMark"> — </span>Patients with HT of FL who are resistant to initial therapy or who relapse following initial therapy have a high likelihood of either not responding to further chemoimmunotherapy or relapsing soon after responding. We encourage such patients to enroll on a clinical trial. Outside of a clinical trial, we favor the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Young, fit patients are evaluated for cellular therapies (CAR-T or allogeneic HCT). For most patients, CAR-T cell therapy is preferred over allogeneic HCT based on extrapolation of studies in DLBCL. (See  <a class="medical medical_review" href="/d/html/4708.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'CD19-directed chimeric antigen receptor-T cell therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are not candidates for cellular therapy are offered serial regimens used for relapsed DLBCL with a plan to perform autologous HCT in those with an at least partial response. Bispecific antibodies and novel agents (eg, targeted therapies) are preferred over cytotoxic chemotherapies.</p><p></p><p class="bulletIndent1">For many targeted therapies, regulatory approval for DLBCL includes approval for large cell lymphoma transformed from indolent lymphoma (eg, <a class="drug drug_general" data-topicid="141559" href="/d/drug information/141559.html" rel="external">epcoritamab</a>, <a class="drug drug_general" data-topicid="141793" href="/d/drug information/141793.html" rel="external">glofitamab</a>, <a class="drug drug_general" data-topicid="129156" href="/d/drug information/129156.html" rel="external">tafasitamab</a> plus <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="131455" href="/d/drug information/131455.html" rel="external">loncastuximab tesirine</a>, and <a class="drug drug_general" data-topicid="121843" href="/d/drug information/121843.html" rel="external">selinexor</a>). (See  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit"</a>.)</p><p></p><p class="bulletIndent1">The targeted therapies have not been directly compared; however, of these, we favor the bispecific antibodies <a class="drug drug_general" data-topicid="141559" href="/d/drug information/141559.html" rel="external">epcoritamab</a> and <a class="drug drug_general" data-topicid="141793" href="/d/drug information/141793.html" rel="external">glofitamab</a> and the combination of <a class="drug drug_general" data-topicid="129156" href="/d/drug information/129156.html" rel="external">tafasitamab</a> plus <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> over others as they are well tolerated and highly active in HT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palliative care is a reasonable alternative for patients who progress despite or are not candidates for these cellular and targeted therapies. (See <a class="local">'Clinical trials'</a> below.)</p><p></p><p>CAR-T cell therapy is an option for those with HT resembling DLBCL who have received two or more lines of systemic therapy, have disease that is refractory to first-line chemoimmunotherapy, or relapse within 12 months of first-line chemoimmunotherapy. As described below, CRs are seen in up to one-half of patients with refractory B cell lymphoma, and responses have been sustained for more than three years. These potential benefits must be weighed against the risk of serious, potentially life-threatening toxicity around the time of infusion. Nonrelapse mortality (NRM) is approximately 5 percent [<a href="#rid58">58</a>]. CAR-T cell therapy is not approved for other histologic subtypes of HT. (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p>Both myeloablative and nonmyeloablative allogeneic HCT have been performed in patients with HT, although the data are limited. HT to DLBCL is listed as an indication for allogeneic HCT referral in guidelines from the American Society for Blood and Marrow Transplantation [<a href="#rid59">59</a>]. While long-term remissions may be attained, NRM can be as high as 25 to 30 percent. Eligibility for allogeneic HCT is discussed separately. (See <a class="local">'Allogeneic hematopoietic cell transplantation'</a> below and  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.) </p><p>Responses to regimens used for relapsed DLBCL alone are short. As an example, the median PFS was 7.7 months in a phase II study of 23 patients with HT treated with single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid60">60</a>]. Similarly, in a phase II study of <a class="drug drug_general" data-topicid="121843" href="/d/drug information/121843.html" rel="external">selinexor</a>, responses were seen in 12 of 31 patients with HT and 23 of 94 patients with de novo DLBCL [<a href="#rid61">61</a>]. For the group as a whole, the median PFS was 2.6 months. (See  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Treatments'</a>.)</p><p class="headingAnchor" id="H784464391"><span class="h2">Chimeric antigen receptor T cells</span><span class="headingEndMark"> — </span>CAR-T cell therapy is an option for those with HT resembling DLBCL who have received two or more lines of systemic therapy, have disease that is refractory to first-line chemoimmunotherapy, or relapse within 12 months of first-line chemoimmunotherapy  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). We offer CAR-T cell therapy to all eligible patients with HT except those with no or limited therapy prior to transformation who achieve a CR with induction therapy. </p><p>CAR-T cells are a form of genetically modified autologous immunotherapy that have shown activity against transformed FL. This customized treatment uses the patient's own T lymphocytes, which are genetically modified (transfected) with a gene that encodes a CAR to direct the patient's T cells against the lymphoma cells. The T cells are genetically modified ex vivo, expanded in a production facility, and then infused back into the patient as therapy.</p><p>Approximately one-half of patients with refractory B cell lymphoma achieve CR in response to CAR-T cells directed against CD19; while the overall durability of these responses remains to be determined, some patients have remissions that are sustained for at least three years [<a href="#rid52">52,62-64</a>]. In a subgroup analysis of a single-arm trial of CAR-T in FL, 6 of 13 patients (46 percent) with heavily pretreated HT of FL achieved CR, with a median duration of response of 10.2 months [<a href="#rid63">63</a>]. No relapses occurred after 15 months, with durable remissions observed for up to 39 months after CAR-T infusion. Various CAR-T constructs have subtle structural differences, even when directed against the same antigen, but they have not been directly compared, and clinical effects of such differences are not yet clear. Other factors that might impact the efficacy of CAR-T cells include the intensity of lymphodepletion and the condition of the T cells from which they are produced.</p><p>CAR-T therapy is associated with serious complications, including rare fatal neurologic events and cytokine release syndrome (CRS), which is a severe systemic response (eg, high fever, flu-like symptoms, hypotension, mental status changes) to the activation and proliferation of CAR-T cells. CRS is observed in nearly all treated patients and may be life-threatening, but it typically responds to treatment with aggressive supportive care that includes <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> and corticosteroids. Neurologic toxicities may also be severe or life-threatening. Other adverse events include hypersensitivity reactions, serious infections, prolonged cytopenias, prolonged hypogammaglobulinemia, and second malignancies. CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) are discussed separately. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a> and  <a class="medical medical_review" href="/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p><a class="drug drug_general" data-topicid="115350" href="/d/drug information/115350.html" rel="external">Axicabtagene ciloleucel</a>, <a class="drug drug_general" data-topicid="114674" href="/d/drug information/114674.html" rel="external">tisagenlecleucel</a>, and <a class="drug drug_general" data-topicid="130728" href="/d/drug information/130728.html" rel="external">lisocabtagene maraleucel</a> are CD19-directed CAR-T immunotherapies that are approved by the US Food and Drug Administration (FDA) for treatment of adults with relapsed or refractory DLBCL after two or more lines of systemic therapy, including DLBCL arising from FL. Axicabtagene ciloleucel and lisocabtagene maraleucel are also FDA approved for large B cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. CAR-T cells are only available in the United States through a risk evaluation and mitigation strategy (REMS), and the FDA labels carry a boxed warning for CRS and neurologic events. Facilities that dispense these agents require special certification, staff must be trained to recognize and manage adverse events, and <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (a humanized monoclonal antibody against the interleukin 6 receptor [IL-6R]) must be available for immediate administration.</p><p>The ZUMA-1 study of <a class="drug drug_general" data-topicid="115350" href="/d/drug information/115350.html" rel="external">axicabtagene ciloleucel</a>, the JULIET study of <a class="drug drug_general" data-topicid="114674" href="/d/drug information/114674.html" rel="external">tisagenlecleucel</a>, and the TRANSCEND study of <a class="drug drug_general" data-topicid="130728" href="/d/drug information/130728.html" rel="external">lisocabtagene maraleucel</a> in relapsed or refractory DLBCL included patients with HT of FL, but subgroup specific data are limited [<a href="#rid52">52,53,65</a>]. These studies are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Chimeric antigen receptor T cell therapy'</a>.)</p><p class="headingAnchor" id="H1776054993"><span class="h2">Autologous transplant</span><span class="headingEndMark"> — </span>A choice to proceed with high-dose therapy and rescue with autologous HCT in patients with HT depends upon the response to therapy, risk of relapse, and ability to meet eligibility requirements. HCT is an option for patients with chemotherapy-sensitive disease who have a high risk of early relapse. Autologous HCT is not effective in those who have no response to chemoimmunotherapy.</p><p>While a proportion of patients with HT will attain a sustained remission following chemoimmunotherapy alone, it is very difficult to identify these patients at the time of diagnosis. Experts differ in their selection of patients for autologous HCT. In general, we offer autologous HCT or CAR-T cell therapy to patients who have been exposed to chemoimmunotherapy prior to HT who achieve a CR to chemoimmunotherapy directed at the HT  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). (See <a class="local">'Consolidation with chimeric antigen receptor T or transplant'</a> above.)</p><p>We do not offer autologous HCT to patients who achieve less than a CR or to patients who present with HT after having received little prior therapy (eg, single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or radiation therapy) or no prior therapy (eg, those presenting with transformation) and have a CR to chemoimmunotherapy directed at the HT. </p><p>Eligibility requirements for autologous HCT are presented separately. (See  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p>No randomized trials have evaluated autologous HCT in this setting. A nonrandomized multicenter cohort study from the Canadian Blood and Marrow Transplant Group reported outcomes of patients with HT who underwent autologous HCT (46 patients), allogeneic HCT (22 patients), or were treated with rituximab-containing chemotherapy without HCT (53 patients) [<a href="#rid56">56</a>]. When compared with the other groups, patients who underwent allogeneic HCT were younger and were more heavily pretreated (including two patients who had progressed despite prior autologous HCT). The following estimated rates were reported by modality:</p><p class="bulletIndent1"><span class="glyph">●</span>Chemoimmunotherapy alone – 61 percent OS and 40 percent PFS at five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autologous HCT – 65 percent OS and 55 percent PFS at five years. Transplant-related mortality 5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allogeneic HCT – 46 percent OS and 46 percent PFS at five years. Transplant-related mortality 23 percent.</p><p></p><p>The lower transplant-related mortality rate and greater experience with autologous HCT in this setting supports our preference for autologous HCT rather than allogeneic HCT as consolidation therapy for most patients with advanced-stage disease and/or those who have received extensive prior therapy. However, this cohort predated the availability of CAR-T cell therapy and other targeted therapies (eg, bispecific antibodies) that are expected to improve outcomes in those treated without HCT [<a href="#rid66">66</a>]. </p><p>Additional retrospective analyses that predated CAR-T cell therapy reported outcomes after autologous HCT in patients with chemotherapy-sensitive disease and a good performance status after HT of FL [<a href="#rid56">56,67-77</a>]. With this approach, approximate four- to five-year disease-free survival ranged from 30 to 60 percent, and OS rates ranged from 40 to 65 percent. However, these values likely underestimate outcomes with modern therapy. As an example, a retrospective study of 147 HCT-eligible patients in first CR, some of whom had access to CAR-T cell therapy, reported an estimated four-year OS of 91 percent [<a href="#rid66">66</a>]. While autologous HCT was associated with delayed progression, an OS benefit was not demonstrated. </p><p>The use of high-dose therapy and autologous HCT in patients with relapsed DLBCL with chemosensitive disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4708.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Autologous hematopoietic cell transplantation'</a>.)</p><p class="headingAnchor" id="H836886653"><span class="h2">Allogeneic hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Allogeneic HCT is only rarely used for HT because of substantial treatment-related mortality and toxicity. However, if CAR-T cell therapy and antibody-based treatments are not available or were previously administered, allogeneic HCT may be considered for select medically fit patients with prior exposure to chemoimmunotherapy who achieve a CR or near-CR with induction chemoimmunotherapy. </p><p>Both myeloablative and nonmyeloablative allogeneic HCT have been performed in patients with HT. Only small case series of highly selected patients have been reported using this approach. HT to DLBCL is listed as an indication for allogeneic HCT referral in guidelines from the American Society for Blood and Marrow Transplantation [<a href="#rid59">59</a>]. Only young, fit patients are candidates for allogeneic HCT.</p><p>A nonrandomized multicenter cohort study from the Canadian Blood and Marrow Transplant Group reported outcomes of 22 patients with HT who underwent allogeneic HCT [<a href="#rid56">56</a>]. The estimated five-year OS and PFS were both 46 percent. Transplant-related mortality at five years was 23 percent. In another report of 18 patients with HT who underwent reduced-intensity conditioning allogeneic HCT, OS and PFS at four years were 60 and 61 percent, respectively [<a href="#rid78">78</a>]. With a median follow-up of 52 months, there were no relapses after one year, suggesting long-term disease control. NRM at one year was 29 percent. Patients with chemotherapy refractory disease have high relapse rates following reduced-intensity conditioning allogeneic HCT.</p><p>The use of allogeneic HCT for FL and DLBCL is discussed separately. (See  <a class="medical medical_review" href="/d/html/88808.html" rel="external">"Allogeneic hematopoietic cell transplantation in follicular lymphoma"</a> and  <a class="medical medical_review" href="/d/html/132087.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit", section on 'Allogeneic hematopoietic cell transplantation'</a>.)</p><p class="headingAnchor" id="H21731452"><span class="h1">PROGNOSIS AND PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Patients with HT historically had a poor prognosis, with a median overall survival (OS) of approximately one to two years [<a href="#rid7">7</a>]. However, outcomes have improved with the availability of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, other targeted therapies, and advances in supportive care surrounding transplantation and chimeric antigen receptor T cell therapy [<a href="#rid4">4,5,47,50,56,75,79-82</a>]. As an example, a prospective observational study of 631 patients with newly diagnosed FL followed for a median of 60 months identified 60 cases of HT with a median OS following HT of 50 months [<a href="#rid3">3</a>]. The estimated rate of survival at five years post-HT was higher for patients who had transformed more than 18 months after FL diagnosis when compared with those who had transformation detected earlier (66 versus 22 percent).</p><p>In another study, patients achieving complete remission had improved survival (40.5 versus 11 months), with the following good prognostic features [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior complete remission for treatment of indolent lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of prior treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Complete remission following treatment for HT</p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum lactate dehydrogenase activity</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of marrow involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of systemic B symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Limited-stage disease</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with a CHOP-like (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) regimen</p><p></p><p>In this study, the time from diagnosis and number of prior relapses did not have an impact on survival after HT. Similar good prognostic factors were noted in a second study [<a href="#rid83">83</a>].</p><p>In another study, attainment of complete remission was associated with the extent of disease at HT, while prior therapy was not [<a href="#rid84">84</a>]. The median survival for patients achieving complete remission was 6.8 years, suggesting that a limited subset of patients with HT treated with CHOP-like regimens experience long survival in remission.</p><p class="headingAnchor" id="H7778922"><span class="h1">CLINICAL TRIALS</span><span class="headingEndMark"> — </span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4724" target="_blank">www.clinicaltrials.gov</a>).</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease scope</strong> – Histologic transformation (HT) refers to the histologic evolution of a clinically indolent non-Hodgkin lymphoma (NHL) subtype (eg, follicular lymphoma [FL]) to a clinically aggressive subtype (eg, diffuse large B cell lymphoma [DLBCL]). HT occurs at a rate of approximately 1 to 2 percent per year. (See <a class="local">'Frequency of transformation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of biopsy for</strong> <strong>diagnosis </strong>– For patients with FL, we typically biopsy at progression to confirm relapse and evaluate for HT. We sample a lymph node with the highest activity on fluorodeoxyglucose (FDG) positron emission tomography; lesions with a standardized uptake value &gt;10 have a higher likelihood of transformation. Other clinical findings that increase the suspicion of HT include rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites, development of systemic symptoms, elevated serum lactate dehydrogenase, and/or hypercalcemia. (See <a class="local">'When to suspect HT'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of HT requires a biopsy of involved tissue (usually an excisional biopsy of a lymph node) that demonstrates loss of the follicular architecture and the accumulation of large tumor cells that resemble those of a clinically aggressive or highly aggressive NHL subtype. Importantly, FL that evolves from low to higher grade (eg, grade 1 to grade 2 or 3a) is <strong>not</strong> considered HT. (See <a class="local">'Clinical presentation and diagnosis'</a> above and <a class="local">'Pathologic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Prior to initiating therapy, a pretreatment evaluation must establish the extent and sites of disease and the performance status of the patient. (See <a class="local">'Pretreatment evaluation and staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Whenever possible, patients should be encouraged to enroll on clinical trials. Palliative care alone is a reasonable alternative, especially for multiply relapsed disease.</p><p></p><p class="bulletIndent1">Outside of a clinical trial, our preferred therapy depends upon prior treatments, the aggressiveness of the tumor (eg, histology and molecular markers), and response to chemoimmunotherapy  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Little or no prior therapy</strong> – For most patients who have received little (eg, single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or radiation therapy) or no prior therapy (eg, presenting with transformation), we offer chemoimmunotherapy used for treatment of de novo cases of the specific aggressive or highly aggressive lymphoma. (See <a class="local">'Little or no prior therapy'</a> above.)</p><p></p><p class="bulletIndent2">As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with HT resembling DLBCL, we offer R-CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) or R-pola-CHP (rituximab, <a class="drug drug_general" data-topicid="121575" href="/d/drug information/121575.html" rel="external">polatuzumab vedotin</a>, cyclophosphamide, doxorubicin, prednisone).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with HT resembling high-grade B-cell lymphoma, not otherwise specified (previously "Burkitt-like" lymphoma) or double-hit HT DLBCL (those with both <em>MYC</em> and <em>BCL-2 </em>rearrangement), we suggest dose-adjusted EPOCH-R (<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>)  (<a class="graphic graphic_table graphicRef88411" href="/d/graphic/88411.html" rel="external">table 5</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">Further management depends on response:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those who achieve a complete response (CR), we suggest observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those with a partial response or no response, we suggest chimeric antigen receptor (CAR)-T cell therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior chemoimmunotherapy</strong> – For patients with HT to DLBCL, we offer R-CHOP or R-pola-CHP, provided that it was not previously administered. For patients who have received prior R-CHOP or O-CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>), we proceed with second-line therapy such as that used for refractory DLBCL (eg, R-ICE [<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>])  (<a class="graphic graphic_algorithm graphicRef122757" href="/d/graphic/122757.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Chemoimmunotherapy regimens'</a>.)</p><p></p><p class="bulletIndent2">For those who achieve a CR, we suggest consolidation with either autologous hematopoietic cell transplantation (HCT) or CAR-T cell therapy rather than chemoimmunotherapy alone or allogeneic HCT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For those who do not achieve a CR, we suggest consolidation with CAR-T cell therapy rather than autologous HCT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prior chemoimmunotherapy'</a> above and <a class="local">'Autologous transplant'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiply refractory disease</strong> – For those with multiply refractory disease, we suggest CAR-T cell therapy rather than allogeneic HCT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), for eligible patients. </p><p></p><p class="bulletIndent2">Patients who are not candidates for cellular therapy are offered serial regimens used for relapsed DLBCL with a plan to perform autologous HCT in those with an at least partial response. Bispecific antibodies and novel agents are preferred over cytotoxic chemotherapies. Palliative care is a reasonable alternative for most patients who progress despite or are not candidates for these cellular and targeted therapies. (See <a class="local">'Multiply relapsed or refractory disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012; 157:188.</a></li><li><a class="nounderline abstract_t">Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165.</a></li><li><a class="nounderline abstract_t">Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013; 31:3272.</a></li><li><a class="nounderline abstract_t">Sarkozy C, Trneny M, Xerri L, et al. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol 2016; 34:2575.</a></li><li><a class="nounderline abstract_t">Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 2015; 126:851.</a></li><li><a class="nounderline abstract_t">Madsen C, Plesner TL, Bentzen HH, et al. Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. Leuk Lymphoma 2020; 61:2584.</a></li><li><a class="nounderline abstract_t">Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426.</a></li><li><a class="nounderline abstract_t">Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15:1587.</a></li><li><a class="nounderline abstract_t">Giné E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17:1539.</a></li><li><a class="nounderline abstract_t">Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 2019; 134:761.</a></li><li><a class="nounderline abstract_t">Dreval K, Hilton LK, Cruz M, et al. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood 2023; 142:561.</a></li><li><a class="nounderline abstract_t">Al-tourah A, Chhanabhai M, Gill K, et al. Incidence, predictive factors and outcome of transformed lymphoma: a population-based study from British Columbia. Ann Oncol 2005; 16:v64.</a></li><li><a class="nounderline abstract_t">Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471.</a></li><li><a class="nounderline abstract_t">Mir F, Barrington SF, Brown H, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood 2020; 135:1214.</a></li><li><a class="nounderline abstract_t">Eide MB, Liestøl K, Lingjaerde OC, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 2010; 116:1489.</a></li><li><a class="nounderline abstract_t">Kridel R, Chan FC, Mottok A, et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med 2016; 13:e1002197.</a></li><li><a class="nounderline abstract_t">Zelenetz AD, Chen TT, Levy R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med 1991; 173:197.</a></li><li><a class="nounderline abstract_t">Foon KA, Thiruvengadam R, Saven A, et al. Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. Ann Intern Med 1993; 119:63.</a></li><li><a class="nounderline abstract_t">Viardot Aa, Barth TF, Möller P, et al. Cytogenetic evolution of follicular lymphoma. Semin Cancer Biol 2003; 13:183.</a></li><li><a class="nounderline abstract_t">Boonstra R, Bosga-Bouwer A, Mastik M, et al. Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma. Hum Pathol 2003; 34:915.</a></li><li><a class="nounderline abstract_t">Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003; 122:745.</a></li><li><a class="nounderline abstract_t">Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88:3937.</a></li><li><a class="nounderline abstract_t">Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46:176.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6:130.</a></li><li><a class="nounderline abstract_t">Bouska A, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2014; 123:1681.</a></li><li><a class="nounderline abstract_t">Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.</a></li><li><a class="nounderline abstract_t">Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994.</a></li><li><a class="nounderline abstract_t">Du M, Peng H, Singh N, et al. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995; 86:4587.</a></li><li><a class="nounderline abstract_t">Davies AJ, Lee AM, Taylor C, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005; 19:1459.</a></li><li><a class="nounderline abstract_t">Lossos IS, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood 2000; 96:635.</a></li><li><a class="nounderline abstract_t">Lossos IS, Warnke R, Levy R. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene. Leukemia 2002; 16:1857.</a></li><li><a class="nounderline abstract_t">Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003; 102:1443.</a></li><li><a class="nounderline abstract_t">Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 2015; 125:658.</a></li><li><a class="nounderline abstract_t">Kridel R, Mottok A, Farinha P, et al. Cell of origin of transformed follicular lymphoma. Blood 2015; 126:2118.</a></li><li><a class="nounderline abstract_t">Ghesquières H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006; 24:5234.</a></li><li><a class="nounderline abstract_t">Noy A, Schöder H, Gönen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009; 20:508.</a></li><li><a class="nounderline abstract_t">Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643.</a></li><li><a class="nounderline abstract_t">Natkunam Y, Warnke RA, Zehnder JL, et al. Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol 2000; 24:525.</a></li><li><a class="nounderline abstract_t">Mohamed AN, Palutke M, Eisenberg L, Al-Katib A. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 2001; 126:45.</a></li><li><a class="nounderline abstract_t">Natkunam Y, Soslow R, Matolcsy A, et al. Immunophenotypic and genotypic characterization of progression in follicular lymphomas. Appl Immunohistochem Mol Morphol 2004; 12:97.</a></li><li><a class="nounderline abstract_t">Fisher DE, Jacobson JO, Ault KA, Harris NL. Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. Cancer 1989; 64:1879.</a></li><li><a class="nounderline abstract_t">Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8:1163.</a></li><li><a class="nounderline abstract_t">Robertson LE, Redman JR, Butler JJ, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 1991; 9:236.</a></li><li><a class="nounderline abstract_t">Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol 1994; 101:305.</a></li><li><a class="nounderline abstract_t">McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol 2020; 191:363.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed on June 30, 2023).</li><li><a class="nounderline abstract_t">Rusconi C, Anastasia A, Chiarenza A, et al. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol 2019; 185:713.</a></li><li><a class="nounderline abstract_t">Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 2022; 386:351.</a></li><li><a class="nounderline abstract_t">Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 2015; 170:504.</a></li><li><a class="nounderline abstract_t">Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 2013; 163:487.</a></li><li><a class="nounderline abstract_t">Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol 2017; 178:699.</a></li><li><a class="nounderline abstract_t">Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377:2531.</a></li><li><a class="nounderline abstract_t">Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839.</a></li><li><a class="nounderline abstract_t">Gleeson M, Hawkes EA, Peckitt C, et al. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. Leuk Lymphoma 2017; 58:1805.</a></li><li><a class="nounderline abstract_t">Wang Y, Link BK, Witzig TE, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood 2019; 134:1289.</a></li><li><a class="nounderline abstract_t">Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 2013; 31:1164.</a></li><li><a class="nounderline abstract_t">Chin CK, Rodriguez MA, Qing Y, et al. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 2020; 61:2985.</a></li><li><a class="nounderline abstract_t">Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv 2023; 7:6589.</a></li><li class="breakAll">2021 Consultation Guidelines. https://bethematchclinical.org/workarea/downloadasset.aspx?id=3545 (Accessed on September 18, 2019).</li><li><a class="nounderline abstract_t">Czuczman MS, Vose JM, Witzig TE, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 2011; 154:477.</a></li><li><a class="nounderline abstract_t">Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7:e511.</a></li><li><a class="nounderline abstract_t">Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 2017; 377:2545.</a></li><li><a class="nounderline abstract_t">Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 2019; 134:636.</a></li><li><a class="nounderline abstract_t">Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099.</a></li><li><a class="nounderline abstract_t">Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380:45.</a></li><li><a class="nounderline abstract_t">Chin CK, Lim KJ, Lewis K, et al. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol 2020; 191:806.</a></li><li><a class="nounderline abstract_t">Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998; 9:865.</a></li><li><a class="nounderline abstract_t">Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5:262.</a></li><li><a class="nounderline abstract_t">Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19:727.</a></li><li><a class="nounderline abstract_t">Chen CI, Crump M, Tsang R, et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001; 113:202.</a></li><li><a class="nounderline abstract_t">Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7:294.</a></li><li><a class="nounderline abstract_t">Berglund A, Enblad G, Carlson K, et al. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65:17.</a></li><li><a class="nounderline abstract_t">Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74:2579.</a></li><li><a class="nounderline abstract_t">Sabloff M, Atkins HL, Bence-Bruckler I, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13:956.</a></li><li><a class="nounderline abstract_t">Villa D, Crump M, Keating A, et al. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol 2013; 24:1603.</a></li><li><a class="nounderline abstract_t">Madsen C, Pedersen MB, Vase MØ, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol 2015; 26:393.</a></li><li><a class="nounderline abstract_t">Kuruvilla J, MacDonald DA, Kouroukis CT, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood 2015; 126:733.</a></li><li><a class="nounderline abstract_t">Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:426.</a></li><li><a class="nounderline abstract_t">Bains P, Al Tourah A, Campbell BA, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 2013; 24:428.</a></li><li><a class="nounderline abstract_t">Reddy N, Oluwole O, Greer JP, et al. Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation. Clin Lymphoma Myeloma Leuk 2012; 12:406.</a></li><li><a class="nounderline abstract_t">Ban-Hoefen M, Kelly JL, Bernstein SH, et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 2012; 53:830.</a></li><li><a class="nounderline abstract_t">Smith SD, Bolwell BJ, Advani AS, et al. High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. Leuk Lymphoma 2009; 50:1625.</a></li><li><a class="nounderline abstract_t">Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13:1726.</a></li><li><a class="nounderline abstract_t">Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25:1268.</a></li></ol></div><div id="topicVersionRevision">Topic 4724 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22348437" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence, risk factors and outcome of histological transformation in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838711" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897955" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27298402" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26105149" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33167719" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485708" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193357" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940035" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300404" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37084389" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence, predictive factors and outcome of transformed lymphoma: a population-based study from British Columbia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6548796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The natural history of initially untreated low-grade non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31961926" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505157" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959929" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898660" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498765" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12959349" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cytogenetic evolution of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562288" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930384" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916960" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362818" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388756" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Genetics of follicular lymphoma transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037725" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400281" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : p53 mutations are associated with histologic transformation of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400252" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : p53 mutation is associated with progression in follicular lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541549" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902285" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10887128" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200704" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738680" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452615" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26307535" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cell of origin of transformed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043351" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139176" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837966" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757399" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343778" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15354733" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunophenotypic and genotypic characterization of progression in follicular lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2790699" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1694234" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988571" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135186" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32579717" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The investigation and management of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32579717" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The investigation and management of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793297" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904799" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907897" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24111533" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28782811" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226797" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888407" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27931133" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350266" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401459" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628087" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672383" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672383" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707581" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32589977" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226764" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31648294" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668228" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30501490" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33065767" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9789609" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10465106" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157024" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328303" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11400952" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914935" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2804380" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640600" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425946" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411416" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26109202" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064981" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035152" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22981964" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22023518" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672775" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7602362" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Long-term survival after histologic transformation of low-grade follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688461" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
